CAMBRIDGE, Mass.– ConcertAI, a leader in multi-modal data and agentic AI solutions for life sciences and healthcare, has named Casey Graves general manager of its Clinical Solutions business. Graves will oversee strategy, partnerships, and product innovation in oncology-focused real-world data (RWD) and AI solutions, with the goal of advancing cancer research and improving patient outcomes.
In his new role, Graves will lead cross-functional teams spanning product development, data science, clinical operations, and commercial strategy. He will also direct partnerships across the oncology ecosystem, including stewardship of the CancerLinQ® initiative, a collaboration designed to accelerate advances in cancer care.
“Casey’s proven leadership in scaling healthcare SaaS solutions and his deep expertise in AI and analytics are a tremendous asset to our team,” said Eron Kelly, CEO of ConcertAI. “As the general manager of our newly created and combined business unit overseeing RWE, Clinical Trials, and CancerLinQ, Casey steps into a vital leadership role. His vision and experience will be invaluable as we continue to enhance these offerings to deliver even greater impact for oncology care teams and the patients they serve.”
Graves brings decades of experience in healthcare technology, including senior roles at Merative, IBM Watson Health, and Deloitte Consulting. At Merative, he managed the Truven Health Insights and MarketScan businesses with a profit and loss responsibility of more than $200 million, executing product modernization and growth strategies during the company’s transition from IBM Watson Health. At IBM, he led multiple provider-focused business units, while at Deloitte, he co-founded the Innovation Lab and launched early AI solutions for health systems.
Most recently, Graves served as a board advisor and consultant for emerging healthcare AI companies, giving him a vantage point on the sector’s rapidly shifting technology landscape.
Graves’ appointment comes as ConcertAI expands its portfolio of AI-powered solutions for oncology. The company has positioned itself at the intersection of clinical research and care delivery, aiming to bridge gaps between data-driven insights and real-world applications in cancer treatment.
